Surmodics Beheer
Beheer criteriumcontroles 2/4
De CEO Surmodics is Gary Maharaj, benoemd in Dec2010, heeft een ambtstermijn van 13.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.53M, bestaande uit 18.2% salaris en 81.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.42% van de aandelen van het bedrijf, ter waarde $ 7.62M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.5 jaar en 13.9 jaar.
Belangrijke informatie
Gary Maharaj
Algemeen directeur
US$3.5m
Totale compensatie
| Percentage CEO-salaris | 18.2% |
| Dienstverband CEO | 13.9yrs |
| Eigendom CEO | 1.4% |
| Management gemiddelde ambtstermijn | 6.5yrs |
| Gemiddelde ambtstermijn bestuur | 13.9yrs |
Recente managementupdates
Recent updates
There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump
Jun 06
Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?
May 30Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital
May 02We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt
Sep 17News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts
Jun 26An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued
Jun 22Is Surmodics (NASDAQ:SRDX) A Risky Investment?
May 14Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher
Apr 17Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package
Feb 03Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?
Jan 08Surmodics gets additional $125M in credit facility
Oct 17Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M
Jul 27Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)
Jul 22Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?
May 03Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why
Feb 04Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?
Dec 24Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$1m |
| Mar 31 2024 | n/a | n/a | US$14m |
| Dec 31 2023 | n/a | n/a | US$6m |
| Sep 30 2023 | US$4m | US$640k | -US$2m |
| Jun 30 2023 | n/a | n/a | -US$23m |
| Mar 31 2023 | n/a | n/a | -US$36m |
| Dec 31 2022 | n/a | n/a | -US$32m |
| Sep 30 2022 | US$3m | US$620k | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$13m |
| Mar 31 2022 | n/a | n/a | -US$10m |
| Dec 31 2021 | n/a | n/a | US$2m |
| Sep 30 2021 | US$3m | US$602k | US$4m |
| Jun 30 2021 | n/a | n/a | US$2m |
| Mar 31 2021 | n/a | n/a | US$7m |
| Dec 31 2020 | n/a | n/a | US$701k |
| Sep 30 2020 | US$3m | US$585k | US$1m |
| Jun 30 2020 | n/a | n/a | US$8m |
| Mar 31 2020 | n/a | n/a | US$7m |
| Dec 31 2019 | n/a | n/a | US$6m |
| Sep 30 2019 | US$2m | US$568k | US$8m |
| Jun 30 2019 | n/a | n/a | US$2m |
| Mar 31 2019 | n/a | n/a | -US$2m |
| Dec 31 2018 | n/a | n/a | -US$2m |
| Sep 30 2018 | US$2m | US$551k | -US$4m |
Compensatie versus markt: De totale vergoeding ($USD 3.53M ) Gary } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).
Compensatie versus inkomsten: De vergoeding van Gary is gestegen terwijl het bedrijf verliesgevend is.
CEO
Gary Maharaj (61 yo)
13.9yrs
Tenure
US$3,527,263
Compensatie
Mr. Gary R. Maharaj has been the Chief Executive Officer and President at Surmodics, Inc. since December 27, 2010. Mr. Maharaj served as the Chief Executive Officer and President at Arizant Inc. from 2006...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 13.9yrs | US$3.53m | 1.42% $ 7.6m | |
| Senior VP of Finance & Information Technology and CFO | 6.5yrs | US$1.30m | 0.54% $ 2.9m | |
| Senior VP of Legal | 4.5yrs | US$1.10m | 0.16% $ 842.5k | |
| Senior VP & President of Medical Device Coatings | 20.1yrs | US$1.12m | 0.38% $ 2.1m | |
| Senior VP & President of Vascular Interventions | 2.5yrs | US$1.49m | 0.26% $ 1.4m | |
| Corporate Controller | 6.5yrs | geen gegevens | 0.058% $ 313.0k | |
| Director of Corporate Development | no data | geen gegevens | geen gegevens | |
| Senior VP of Human Resources & President of In Vitro Diagnostics | 4.6yrs | US$970.92k | 0.45% $ 2.4m |
6.5yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van SRDX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 13.9yrs | US$3.53m | 1.42% $ 7.6m | |
| Independent Director | 10.8yrs | US$186.50k | 0.26% $ 1.4m | |
| Independent Director | 13.8yrs | US$185.00k | 0.27% $ 1.4m | |
| Independent Non-Executive Chair of the Board | 16.8yrs | US$229.00k | 0.23% $ 1.2m | |
| Independent Director | 22.8yrs | US$176.50k | 0.20% $ 1.1m | |
| Independent Director | 7.6yrs | US$176.50k | 0.088% $ 472.3k |
13.9yrs
Gemiddelde duur
69yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van SRDX zijn ervaren en ervaren (gemiddelde ambtstermijn van 13.9 jaar).